查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198339

单细胞基因组测序市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Single-Cell Genome Sequencing Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

单细胞基因组测序市场预计在 2022 年至 2027 年的预测期内以 15.2% 的复合年增长率增长。

COVID-19 大流行对所研究的市场产生了积极影响。 关于 COVID-19 对单细胞测序的影响的各种研究已经发表。 例如，2020 年 9 月发表的题为“COVID-19 患者免疫反应的单细胞景观”的研究表明，由严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染引起的冠状病毒病 (COVID-19)这项名为“疾病严重程度与宿主免疫反应之间的关係尚未完全了解”的研究对疾病严重程度与宿主免疫反应之间的关係知之甚少。 单细胞测序显示 COVID-19 患者的大多数细胞类型都有强烈的干扰素-ALPHA 反应和整体急性炎症反应。 这些研究提供了对单细胞测序在 COVID-19 中应用的见解。 同样，在 2022 年 2 月，另一项名为“Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+Monocytes and Memory CD8+T Cells Involved in Severe COVID-19”的研究将显示轻度和重度感染之间的差异。据报导，感染之间存在较大的基因调节免疫学变化。 包括遗传风险基因表达升高、炎性细胞因子增加和功能性免疫细胞亚群增加，这些都会加剧疾病的严重程度。 因此，此类研究提供了对 COVID-19 的洞察力，从而增加了未来的市场增长。

疾病增多、主要市场参与者的举措以及资金增加等因素预计将推动市场增长。 新兴市场的发展可能会推动该地区的药物开发进程，并最终由于设备提供的优势而导致研究市场的扩大。 例如，根据 2020 年 9 月发表的一篇文章，有 220 万，比美国国立卫生研究院 (NIH) 资助的 2300 亿美元的国家卫生研究发表的与生物製剂或靶标相关的研究多出 21%。 生物技术领域的此类资金增加了 PCR 设备（包括单细胞测序）的研究和使用，推动了市场增长。 此外，市场参与者和研究机构之间使用测序仪研究和开发新的诊断和治疗方法的合作也在推动市场的增长。 例如，2020 年 1 月，Illumina 和以色列的 Danyel Biotech 报告说，以色列魏茨曼科学研究所的科学家正在使用 Illumina 的下一代测序 (NGS) 技术。 Weizmann 是单细胞基因组学的先驱，Illumina 的技术将使研究所的研究人员能够进一步发展这一新兴的研究领域。 新安装的系统还将扩大以色列的基因组研究能力。 实验室正在使用 NovaSeq 6000 系统研究免疫系统内的细胞如何与健康组织和肿瘤细胞相互作用。 NovaSeq 6000 的使用使研究人员能够对基因组、表观基因组和转录组（RNA 序列）进行测序，这有望推动被调查市场的增长。 因此，由于上述因素，未来市场可能会增长。

但是，与单细胞基因组测序相关的分析挑战可能会阻碍市场增长。

单细胞基因组测序市场趋势

预计在预测期内 PCR 领域将占据重要的市场份额

预计 PCR 部分在预测期内将占据很大的市场份额。

主要市场参与者的举措（例如产品发布和合作研究）等因素预计将在预测期内推动市场增长。 细分市场的增长是由产品引入市场推动的。 例如，2020 年 6 月，Stilla Technologies 推出了全球首款六色数字 PCR 仪器之一，名为“六色棱镜”。 该设备可广泛应用于肿瘤、传染病、基因治疗、疾病监测、食品检测等领域。 同样，2022 年 7 月，Bio-Rad 推出了 CFX Opus Deepwell 实时 PCR 检测系统。 Bio-Rad 的 CFx Opus Deepwell 实时 PCR 检测系统旨在支持研究人员开发核酸检测分析。

此外，参与者之间的战略合作推动了该细分市场的发展，以加强全球竞争。 例如，2021 年 10 月，PerkinElmer 和 Honeycomb Biotechnologies 宣布推出全球首个用于单细胞分离和分析的 HIVE scRNAseq 解决方案。 HIVE 解决方案利用便携式手持设备捕获、存储和製备各种细胞类型的 RNA-Seq 文库，包括粒细胞、肾单位、肝细胞和神经元等脆弱和不稳定的细胞。 由于 HIVE 不需要专门的设备，它扩大了实验室进行基础、转化、临床和临床前研究的可能性。

因此，由于上述因素，市场的 PCR 部分预计在预测期内将出现大幅增长。

北美有望在预测期内主导市场

预计在预测期内，北美将占据市场的主导份额。

疾病流行率上升以及主要市场参与者的产品发布和扩张等因素预计将推动该地区的市场增长。 根据美国癌症协会杂誌发表的“2021 年癌症统计数据”，美国估计有 190 万新癌症病例和 608,570 例死亡病例将显着推动市场。 同样，根据 Globocan 2020 的数据，2020 年该国估计将有 195,449 例新癌症病例。 预计在预测期内，该国癌症患者人数将增加，从而推动市场增长。

此外，基于单细胞测序的新产品的推出将极大地推动市场的增长。 例如，2020 年 9 月，Roche获得美国食品药品监督管理局 (FDA) 的批准，用于美国全自动 cobas 6800/8800 系统的 cobas HIV-1/HIV-2 定性检测。 该测试将帮助医疗保健专业人员在一次测试中做出确认 HIV 诊断和确定适当治疗所需的关键 HIV-1 和 HIV-2 区分。 2021 年 10 月，Takara Bio Inc. 的全资子公司 Takara Bio USA Inc. 推出了用于 ICELL8 cx 单细胞系统的 SMART-Seq Pro 试剂盒。 科学家们将使用这种自动化的单细胞 RNA-seq 技术同时从 1,500 多个单细胞中收集全长转录组数据，这些数据来自广泛的样本类型，包括巨大而脆弱的成人心肌细胞。 此外，在 2020 年 3 月，为了应对 COVID-19 公共卫生挑战，基于剑桥的推理创建了世界上第一个用于合成异构单细胞 RNA 测序 (scRNA-seq) 数据集的软件资源。宣布它做到了。 这个图书馆了解超过 1 亿篇非结构化生物医学论文，nferX 增强智能使您能够将科学文献中的新发现与单细胞水平的深层生物信号相关联它配备了技术。

因此，由于这些因素，所研究的市场预计在预测期内将显着增长。

单细胞基因组测序市场竞争者分析

市场部分分散，由几个主要参与者组成。 目前主导市场的一些公司是 Fluidigm Corporation、QIAGEN、Illumina, Inc.、F. Hoffmann-La Roche Ltd. 和 ThermoFisher Scientific, Inc.。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 对单细胞基因组学的高研发投资
    • 增加 SCG 中心和核心设施
  • 市场製约因素
    • 与单细胞基因组测序相关的分析挑战
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（按价值计算的市场规模:百万美元）

  • 产品名称
    • 设备
    • 试剂
  • 技术领域
    • 音序器
    • 聚合□链反应
    • 微阵列
    • 其他
  • 申请
    • 癌症
    • 免疫学
    • 微生物学
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • 10x Genomics
    • BD
    • BGI
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fluidigm Corporation
    • Illumina, Inc.
    • Oxford Nanopore Technologies plc.
    • PacBio
    • QIAGEN
    • Takara Bio Inc
    • ThermoFisher Scientific, Inc.

第七章市场机会与未来趋势

简介目录
Product Code: 90594

The Single-cell Genome Sequencing Market is projected to register a CAGR of 15.2% during the forecast period 2022-2027.

The COVID-19 pandemic had a positive effect on the studied market. Various research studies have been published about the impact of COVID-19 on single-cell sequencing. For Instance, in September 2020, research published titled "Single-cell landscape of Immunological Responses in Patients with COVID-19" stated that coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host immune response is not fully understood. When single-cell sequencing was performed, most cell types in patients with COVID-19 showed a strong interferon-α response and an overall acute inflammatory response. Such studies provide inside into the application of single-cell sequencing on COVID-19. Similarly, in February 2022, another research study titled "Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+ Monocytes and Memory CD8+T Cells Involved in Severe COVID-19" stated that there was a major genetics-modulated immunological shift between mild and severe infection, including an elevated expression of genetics-risk genes, increase in inflammatory cytokines, and of functional immune cell subsets aggravating disease severity, which provides novel insights into parsing the host genetic determinants that influence peripheral immune cells in severe COVID-19. Hence, such studies provide insight into COVID-19 and thus increase the market growth in the future.

Factors such as increasing diseases, initiatives by key market players, and increased funding are expected to increase the market growth. Rising disease prevalence is also likely to boost the drug development processes in the region, ultimately leading to the studied market expansion owing to the benefits offered by the devices. For Instance, as per the article titled ' United States Tax Dollars Funded Every New Pharmaceutical in the Last Decade' published in September 2020 2.2 million published research related to the biological drugs or targets of which 21% acknowledged funding from National Institutes of Health (NIH) of more than than USD 230 Billion. Such funding in the biotechnology field increases the research and the usage of PCR devices (including single-cell sequencing), boosting the market's growth. The collaboration among the market players and research institutes for the research and development of new diagnostics and treatment methods with the help of the sequencing method is also boosting the market's growth. For Instance, in January 2020, Illumina and Israel-based Danyel Biotech reported that scientists at the Weizmann Institute of Science in Israel are now using Illumina's next-generation sequencing (NGS) technology. Weizmann has been a pioneer of single-cell genomics, and Illumina's technology will enable the Institute's researchers to continue advancing this fast-growing field of research. The newly-installed system also expands genomic research capacity within Israel. The institutes are using NovaSeq 6000 system to investigate how cells within the immune system interact with healthy tissue and tumor cells. Since the use of NovaSeq 6000 enables researchers to sequence the genome, epigenome, and transcriptome (RNA sequence), it is expected to drive the growth of the studied market. Thus, due to the abovementioned factors, the market is likely to grow in the future.

However, analytical challenges related to single-cell genome sequencing will hinder the market's growth.

Single Cell Genome Sequencing Market Trends

PCR Segment is Expected to Hold a Significant Market Share Over the Forecast Period

The PCR segment is expected to hold a significant share in the market over the forecast period.

Factors such as initiatives by key market players such as product launches and collaborations are expected to increase the market growth in the forecast period. The market segment's growth is boosted by the launch of products in the market. For instance, in June 2020, Stilla Technologies launched one of the world's first six-color digital PCR instruments named 'the six-color Prism'. This system can be used widely in oncology, infectious disease, gene therapy, disease monitoring, and food testing. Similarly, in July 2022 Bio-Rad launched CFX Opus Deepwell real-time PCR detection system. Bio-Rad's CFx Opus Deepwell Real-time PCR Detection system is designed to support research in developing nucleic acid detection assays.

Additionally, the market segment is boosted by the strategic collaboration among the players to strengthen the opposition worldwide. For instance, in October 2021, PerkinElmer and Honeycomb Biotechnologies announced the launch of the first-of-its-kind HIVE scRNAseq Solution for single-cell isolation and analysis. The HIVE solution leverages a portable, handheld device for the capture, storage, and RNA-Seq library preparation of a diverse range of cell types, including fragile and labile cells such as granulocytes, nephrons, hepatocytes, and neurons. The HIVE solution requires no specialized instrumentation and expands opportunities for laboratories pursuing basic, translational, clinical, and preclinical research.

Thus, owing to the abovementioned factors, the PCR segment of the market is expected to project considerable growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to hold a dominant share in market over the forecast period.

Factors such as rising disease prevalence and product launches and expansions by key market players are expected to drive market growth in the region. According to Cancer Statistics 2021, published in the American Cancer Society Journal, an estimated 1.9 million new cancer cases are diagnosed and 608,570 cancer deaths in the United States, which will drive the market significantly. Similarly, according to data by Globocan 2020, the country's estimated number of new cancer cases in 2020 was 195,449. The number of cancer cases in the country is expected to increase during the forecast period, thus driving the market's growth.

Furthermore, launching new products based on single-cell sequencing will drive market growth significantly. For instance, in September 2020, Roche received United States Food and Drug Administration (FDA) approval for the Cobas HIV-1/HIV-2 Qualitative Test for use on the fully automated Cobas 6800/8800 Systems in the US. The test will help healthcare professionals confirm HIV diagnosis with a single test and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options. In October 2021, Takara Bio USA, Inc., a fully owned subsidiary of Takara Bio Inc., launched the SMART-Seq Pro kit for the ICELL8 cx Single-Cell System. Scientists can collect full-length transcriptome data from over 1,500 single cells simultaneously using this automated single-cell RNA-seq technology from a wide range of sample types, including huge, delicate adult cardiomyocytes. Furthermore, in March 2020, to fight the COVID-19 public health problem, inference, a Cambridge-based company, announced the creation of a first-of-its-kind software resource that synthesizes disparate Single Cell RNA-sequencing (scRNA-seq) data sets. The library includes the nferX augmented intelligence technology, which enables machines to understand over 100 million unstructured biomedical papers and correlate emerging insights from scientific literature with deep biological signals at the single-cell level.

Thus, due to the such factors, the studied market is expected to grow significantly during the forecast period.

Single Cell Genome Sequencing Market Competitor Analysis

The market is partially fragmented and consists of several major players. Some companies currently dominating the market are Fluidigm Corporation, QIAGEN, Illumina, Inc., F. Hoffmann-La Roche Ltd., and ThermoFisher Scientific, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High R&D Investments in the Single cell Genomics
    • 4.2.2 Growing Number of SCG Centers and Core Facilities
  • 4.3 Market Restraints
    • 4.3.1 Analytical Challenges Related to Single-cell Genome Sequencing
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product
    • 5.1.1 Instruments
    • 5.1.2 Reagents
  • 5.2 Technology
    • 5.2.1 Sequencing
    • 5.2.2 PCR
    • 5.2.3 Microarray
    • 5.2.4 Others
  • 5.3 Application
    • 5.3.1 Cancer
    • 5.3.2 Immunology
    • 5.3.3 Microbiology
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 10x Genomics
    • 6.1.2 BD
    • 6.1.3 BGI
    • 6.1.4 Bio-Rad Laboratories, Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd.
    • 6.1.6 Fluidigm Corporation
    • 6.1.7 Illumina, Inc.
    • 6.1.8 Oxford Nanopore Technologies plc.
    • 6.1.9 PacBio
    • 6.1.10 QIAGEN
    • 6.1.11 Takara Bio Inc
    • 6.1.12 ThermoFisher Scientific, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS